ARTICLE
Five Takeaways: An In-Depth Look at the Federal Legislative Game Plan to Support Renewables
May 15, 2020
Read time: 3 min
On Thursday May 14, McDermott was joined by Gregory Wetstone, president and chief executive officer of the American Council on Renewable Energy (ACORE) to discuss the latest market updates on the severe disruption and uncertainty brought on the renewables industry by COVID-19.
Five takeaways from this week’s webinar below:
1.There is no clear insight yet into what a congressional relief package regarding renewable energy might look like, despite the fact that congress is discussing its fifth COVID-19-related response bill.
2. Even though the outlook was already pessimistic, clean energy job loss has been worse than expected; there has been a loss of 94,000 jobs in the renewable sector between March and April and 600,000 additional unemployment claims across the clean energy sector.
3. Renewables have a great potential to continue to be part of the nation’s economic recovery; two of the fastest growing job categories in the nation have been wind turbine technicians and solar panel installer.
4. Senior Department of Energy officials have reassured that the recent bulk power executive order is a continuation of existing policies regarding transmission corridors and is not targeted at renewables, which are recognized as valuable for national security. See the Office of Electricity’s Q&A and contact email for a response to President Trump’s signed Executive Order, “Securing the United States Bulk-Power System” and join McDermott on May 21 for a legal analysis of the EO.
5. The commerce department is undertaking an investigation which could lead to the imposition of additional tariffs, particularly in regards to transformers; the timing for these tariffs (if enacted) is likely right before the election.
To begin receiving Energy updates, including invitations to the Renewables Roundtable and Q&A Webinar Series, please click here.
To access past webinars, please click here.

Accelerated market access for drugs and vaccines under development to combat COVID-19
ARTICLE
Accelerated market access for drugs and vaccines under development to combat COVID-19
May 2020
Read time: 2 min
One key to successfully combating COVID-19 lies in clinical research. Currently, almost all large research-based pharmaceutical manufacturers and a large number of other pharmaceutical companies and research institutions are in a global race to develop effective drugs and vaccines against the disease. Companies and institutions usually need many years to carry out preclinical and clinical research into a medicinal product or vaccine and obtain a marketing authorisation for their product.

Trade Secret Misappropriators Fail to Launch in Rocket Facility
ARTICLE
Trade Secret Misappropriators Fail to Launch in Rocket Facility
May 14, 2020
Read time: 6 min
Addressing a variety of challenges to a judgment against defendants in a trade secret misappropriation action, the US Court of Appeals for the Third Circuit found that the plaintiff had standing on the basis of lawful possession (as opposed to ownership) of the trade secret materials and that the damages awarded, including punitives, was supported by sufficient evidence. Advanced Fluid Systems, Inc. v. Huber, Case Nos. 19-1722; -1752 (3d Cir. Apr. 30, 2020) (Jordan, J.).
Advanced Fluid Systems (AFS) makes hydraulic systems. Kevin Huber was a sales engineer for AFS, and later founded INSYSMA. Livingston & Haven competes with AFS. Clifton Vann is the president of Livingston and the CEO of its holding company. Thomas Aufiero worked at AFS from 1989 to 2011, then became a regional sales manager at Livingston.
In 2009, AFS contracted with the Virginia Commonwealth Space Flight Authority to install hydraulic systems for the NASA rocket launch facility on Wallops Island, Virginia. Orbital Sciences uses the Wallops Island facility to launch its Antares rocket, using a hydraulic system designed and installed by AFS. While AFS provided the Authority with engineering drawings relating to the hydraulic system, the drawings were the property of the Authority. In September 2012, the Authority experienced financial difficulty, resulting in Orbital acquiring control of the launch system.
Huber, while still working for AFS, began communicating with Livingston, Vann and Aufiero (collectively, the Livingston parties), claiming that Orbital was unhappy with AFS and wanted new vendors. Huber helped the Livingston parties become familiar with the hydraulic system and Orbital’s operations. He arranged tours and sent the Livingston parties confidential AFS internal documents and engineering drawings. The Livingston parties created a Dropbox folder, installed a virtual private network on Huber’s AFS laptop, and provided Huber with a Livingston email address. When Orbital sought bids for two projects, Huber worked closely with Livingston to prepare bids, undermined AFS’s bids (including by inflating their price and withholding relevant information) and continued providing Livingston with confidential AFS documents.
About a month later, Huber formed INSYSMA to compete for one of the contracts. He downloaded 98 gigabytes of AFS’s proprietary files, including all of its pending and past project files dating back to 1993. Huber then resigned from AFS. Huber continued to work with Livingston, including by sharing the stolen AFS files. Livingston relied heavily on the AFS files and other insider knowledge from Huber in preparing and submitting its bids. Ultimately, Orbital awarded Livingston one of the contracts and INSYSMA the other.
AFS brought suit against Huber, INSYSMA, the Livingston parties and Orbital. AFS settled with Orbital in exchange for a subcontract. The settlement provided that “no money is being paid” by Orbital in respect of AFS’s claims against Huber, INSYSMA or the Livingston parties. As to the other parties, the district court granted summary judgment that Huber and INSYSMA had misappropriated AFS’s trade secrets, and held a bench trial on AFS’s remaining claims. The Livingston parties’ counsel, Philip Morin, informed the court that he was not admitted to practice before it and that he was subject to disciplinary action in other states. Nonetheless, the district court permitted Morin to continue to represent the Livingston parties. After the trial, the district court ordered the parties to file proposed findings of fact and conclusions of law. AFS, Huber and INSYSMA filed submissions, but the Livingston parties never filed any. Morin did not disclose this failure to the Livingston parties. The district court found that the Livingston parties were liable for misappropriating AFS’s trade secrets; that Huber had breached a duty of loyalty to AFS; and that Livingston and Vann, but not Aufiero, aided and abetted that breach. The district court then awarded AFS compensatory damages (lost profits) from Huber, INSYSMA and the Livingston parties; punitive damages against Huber for trade secret theft; and punitive damages against Huber, Livingston and Vann for the breach of fiduciary duty.
The defendants appealed, raising a variety of issues.
Standing. Defendants argued that AFS had no standing to sue for misappropriation of information that it did not own or lawfully possess. The Third Circuit rejected this argument, explaining that ownership (as opposed to lawful possession) is not required, and that AFS did, in fact, lawfully possess the information. Defendants also argued that the information was not protectable as trade secrets because AFS did not take adequate measures to protect its secrecy. The Court rejected this argument as well, notwithstanding the absence of a confidentiality agreement between AFS and the Authority, because the Authority had honored AFS’s proprietary designations and did not disclose its information except as necessary for operation of the hydraulic system.
Counsel. The Livingston parties requested a new trial based on Morin’s misconduct. The Third Circuit rejected these arguments, finding that the Livingston parties were not prejudiced by Morin’s conduct, that the extraordinary relief of a new trial was not warranted, and that it was the Livingston parties’ responsibility to retain and supervise their counsel.
Punitive Damages. Vann and Livingston challenged the punitive damages award because the record lacked evidence that their conduct was sufficiently egregious and because the district court improperly relied on their lack of remorse. The Third Circuit rejected both positions, finding ample evidence of egregious conduct by Vann and Livingston, most notably a compensation package that Vann approved for Huber that incentivized Huber to damage AFS while knowing that Huber owed AFS a duty of loyalty under Pennsylvania law. The Court also held that the district court properly considered Vann’s and Livingston’s lack of contrition as evidence of their state of mind at the time of their wrongdoing.
Offset. Defendants argued that the damages award should be set off by the amount of the Orbital settlement. The Third Circuit rejected this argument because defendants had failed to raise it at or before trial and had effectively denied AFS the opportunity to put on evidence relating to such a theory, and because defendants had failed to prove (or even provide evidence) that Orbital was a joint tortfeasor.
Lost Profits. Defendants challenged the lost profits award as allegedly failing to account for costs that AFS would have incurred in obtaining the lost profits. The Third Circuit sustained the district court’s lost profits award as supported by the evidence of record.
Practice Note: Even when confronted with the most one-sided fact patterns, it is important to formulate and timely disclose damages theories, and prove them at trial.

COVID-19 Ate My Homework – Recent Extensions and Relief for Retirement Plans
ARTICLE / CLIENT ALERT
COVID-19 Ate My Homework – Recent Extensions and Relief for Retirement Plans
May 14, 2020
Read time: 6 min
In recognition of the difficulties faced by retirement plan sponsors, participants and beneficiaries due to the COVID-19 pandemic, new guidance extends the deadlines for notices and disclosures required by Title I of ERISA and extends deadlines for retirement plan participants and beneficiaries to submit benefit claims and benefit appeals. The new guidance also provides some welcome fiduciary relief for electronic disclosures, incomplete plan loan or distribution documentation, and delayed participant contributions and loan repayments.
SUMMARY
The Department of Labor (DOL), in conjunction with the Internal Revenue Service (IRS) and Department of the Treasury, recently issued guidance extending a number of retirement plan deadlines in light of the COVID-19 pandemic, including deadlines for many participant notices and benefit plan claims. However, the new guidance does not extend the 2019 Form 5500 for a calendar-year retirement plan. The guidance also provides fiduciary relief for retirement plans in the areas of electronic disclosures and plan loans, distributions and contributions. Finally, the guidance includes relief applicable to group health plans, which is described here. Plan sponsors, administrators and fiduciaries should be aware of these extensions and other relief as they continue to navigate the impact of the COVID-19 pandemic on their retirement plans.
IN DEPTH
In recognition of the difficulties faced by retirement plan sponsors, participants and beneficiaries due to the COVID-19 pandemic, new guidance extends the deadlines for notices and disclosures required by Title I of the Employee Retirement Income Security Act of 1974 (ERISA), and extends deadlines for plan participants and beneficiaries to submit benefit claims and benefit appeals. The new guidance also provides some welcome fiduciary relief for electronic disclosures, incomplete plan loan or distribution documentation, and delayed participant contributions and loan repayments.
Extension of Certain Disclosures and Notices
The new guidance provides relief to retirement plan administrators for deadlines to furnish ERISA-mandated statements, disclosures and notices beginning on March 1, 2020, and ending 60 days after the announcement of the end of the national emergency (the COVID Period). Specifically, during this COVID Period, required notices may be delayed, provided that the fiduciary acts in good faith and furnishes the communication as soon as practical. Some of the extended notices and disclosures include: annual funding notices, blackout notices, summary annual reports, summary plan descriptions, qualified default investment alternative notices and other notices or disclosures required under Title I of ERISA.
Limited Extension for Form 5500 Filings
Retirement plans subject to ERISA generally must file a Form 5500 by the end of the seventh month after the end of the plan year (for calendar-year plans, the deadline is July 31 of the following year). Guidance previously extended any Form 5500 filing that would otherwise be due between April 1 and July 15, 2020, to a new deadline of July 15, 2020, without the need to request an extension. However, for a calendar-year plan, the 2019 Form 5500 still is due by July 31, 2020, but may be extended using IRS Form 5558 until October 15, 2020.
Expansion of Permitted Electronic Disclosure
The guidance also allows use of alternative electronic means for communicating with retirement plan participants and beneficiaries during the COVID Period, if the fiduciary reasonably believes such individuals have effective access to email, text messaging or the plan sponsor’s intranet or website. The DOL historically resisted allowing plan sponsors to use electronic disclosures, but the expansion of electronic communication during the COVID Period closely follows a proposed DOL regulation to relax electronic disclosure of retirement plan notices and required information. Read our client alert, “DOL issues new proposed rule for electronic disclosures of retirement plan notices,” for a summary of the proposed rule.
Fiduciary Relief for Loans, Distributions and Contributions
The guidance contains relief for plan fiduciaries in connection with retirement plan loans and distributions. Failure to follow procedural requirements for plan loans or distributions will not violate ERISA if:
- The failure is solely attributable to the COVID-19 pandemic;
- The plan administrator makes a good-faith effort to comply with the procedural requirements and
- The plan administrator makes a reasonable attempt to correct any procedural deficiencies, such as assembling missing documentation, as soon as administratively practical.
This relief does not apply to any other requirements under the IRS’s jurisdiction, such as a failure to comply with spousal consent requirements for a retirement plan loan or distribution.
Additional fiduciary relief is granted for participant contributions and loan repayments to retirement plans. Under ERISA, such contributions and repayments generally must be made no later than 15 business days following the month in which the amounts were withheld from payroll (but the DOL generally takes the position that such amounts must be forwarded to a retirement plan’s trust within a few days of payroll). Recognizing that employers and plan service providers may experience difficulties forwarding payments within this timeframe, the DOL provided that it will not take enforcement action with respect to a temporary delay in contributions or repayments to a retirement plan, provided the delay is solely because of the COVID-19 pandemic, occurs during the COVID Period and the plan sponsor forwards such payments as soon as administratively practical.
Extended Benefit Claims and Appeal Timetables
ERISA prescribes certain timeframes during which plan participants or beneficiaries must file benefit claims and appeals, and timeframes during which plan fiduciaries must decide such claims and appeals. The new guidance extends the time for retirement plan participants and beneficiaries to file benefit claims, or file appeals of denied benefit claims. Specifically, retirement plans must disregard the COVID Period in determining the dates by which participants and beneficiaries are required to make benefit claims or benefit appeals. For example, although a plan participant normally must appeal a denied retirement plan claim within 60 days, the deadline for such appeal is extended until the end of the COVID Period. Even though the guidance does not specifically address a fiduciary extension of the period to decide a benefit claim or appeal, notification of such decisions also are likely extended (as a required Title I notice under ERISA).
Conclusion
The recent guidance reflects an acknowledgement that retirement plan sponsors, administrators and participants may be struggling to comply with applicable deadlines and requirements for retirement plans in the midst of the COVID-19 pandemic. Plan sponsors and administrators should consider all available extensions and relief as they continue to administer retirement benefits during 2020.
CMS Announces Additional Blanket Waivers for Healthcare Facilities
ARTICLE / CLIENT ALERT
CMS Announces Additional Blanket Waivers for Healthcare Facilities
May 14, 2020
Read time: 4 min
On May 11, 2020, the Centers for Medicare and Medicaid Services (CMS) issued a new suite of blanket waivers to ensure that healthcare facilities have the flexibility they need to treat patients during the Coronavirus (COVID-19) pandemic. The latest waivers, all of which are effective through the end of the public health emergency declaration, provide for the following:
- Expand hospitals’ ability to offer long-term care services for patients who do not require acute care but meet criteria for skilled nursing facility (SNF) care. CMS has waived various eligibility requirements set forth at 42 CFR § 482.58 to permit hospitals to establish swing beds that will be payable by the SNF prospective payment system. The waiver is intended to permit hospitals to treat patients that no longer require acute care, but are unable to be placed in a SNF due to the COVID-19 emergency. Hospitals that wish to take advantage of the waiver must call their Medicare Administrative Contractor hotline and attest to various criteria, including that they have attempted to exhaust other options, there are no SNFs in their catchment area that are willing to accept patients due to COVID-19, they meet the waiver criteria, and they will discharge the patients as soon as practicable.
- Waive distance requirements, market share and bed requirements for sole community hospitals (SCHs). CMS has waived several eligibility requirements under 42 CFR § 412.92(a) that typically apply to hospitals with SCH status, including the distance requirements. Prior to the waiver, SCHs were concerned that if additional hospitals expanded or opened within their service area to meet COVID-19 caseload demand, and as permitted by other CMS waivers (e.g., the Hospital Without Walls and QSO-20-06-ASC waivers), the expanding hospital might interfere with the SCH’s ability to satisfy the eligibility criteria. This waiver puts those concerns to rest. CMS also waived similar market share and maximum bed requirements for SCHs that qualify on the basis of being located between 25 and 35 miles from other “like” hospitals. The waiver of these requirements provides these particular SCHs with the ability to expand bed capacity to meet demand or to direct patients to other better-suited facilities without risking their SCH status.
- Waive eligibility requirements for Medicare-dependent, small rural hospitals (MDHs). Similar to the waiver for SCHs, CMS has waived certain eligibility requirements for MDHs set forth at 42 CFR § 412.108(a)(1). Specifically, CMS waived the requirements that MDHs have 100 or fewer beds during the cost reporting period and that at least 60% of the MDH’s inpatient days or discharges be attributable to individuals entitled to Medicare Part A benefits during the cost reporting period. This waiver ensures both that MDHs will be able to expand bed capacity to meet surge demand resulting from COVID-19, and that they will not be penalized if their share of Medicare patients decreases, which could occur either because they experience an increase in non-Medicare patients or because Medicare patients are directed to other hospitals.
- Update specific life safety code requirements for certain types of healthcare facilities. CMS announced the easing of certain requirements that apply to hospitals, critical access hospitals, inpatient hospice facilities, intermediate care facilities for individuals with intellectual disabilities, and nursing facilities. Specifically, CMS waived requirements related to placement of alcohol-based hand rub dispensers and quarterly fire drills (instead permitting an orientation training program related to the fire plan), as well as any requirements that would not permit temporary walls and barriers between patients.
A full list of CMS’s blanket waivers is available here.
Rachel Stauffer and Jessica Roth of McDermott+Consulting also contributed to this On the Subject.

TALF 2.0: Private Investment Funds as Eligible Borrowers
ARTICLE / CLIENT ALERT
TALF 2.0: Private Investment Funds as Eligible Borrowers
May 13, 2020
Read time: 5 min
On May 12, 2020, the Federal Reserve Bank of New York (“New York Fed”) announced additional information and details regarding borrower and collateral eligibility criteria for the Term Asset-Backed Securities Loan Facility (“TALF 2.0”) initially announced on March 23, 2020, which was among several extensive measures designed to support the flow of credit to consumers and businesses, discussed in our initial Alert.[1]
In addition to clarifying and expanding upon details of the TALF 2.0, the additional information provides greater insight into the various types of eligible borrowers.
This Alert provides an overview of the borrower eligibility criteria applicable to investment funds seeking to borrow under the TALF 2.0 (“TALF Borrower”).
Investment Funds as TALF Borrowers
A business that owns eligible collateral may borrow from the TALF 2.0 if it (a) is created or organized in the United States or under the laws of the United States; (b) has significant operations in and a majority of its employees based in the United States; and (c) maintains an account relationship with a financial institution that from time to time is a party to the Master Loan and Security Agreement (“TALF Agent”) to be published by the New York Fed (“MLSA”). A borrower that is organized as an investment fund[2] will need to satisfy (a) and (c), whereas its investment manager must satisfy (b).
In order for an investment manager to be deemed to have significant operations in the United States, such manager’s activities in the United States must have generated greater than 50% of its consolidated assets, annual consolidated net income, annual consolidated net operating revenues, or annual consolidated operating expenses (excluding interest expenses and any other expenses associated with debt service), as reflected in its most recent audited financial statements.
Notwithstanding the forgoing, an investment fund will not be eligible to be a TALF Borrower if any party that owns 10% or more of any outstanding class of securities of such fund or its investment manager (in each case, a “Material Investor”) is, directly or indirectly, a foreign government. In addition, the New York Fed will publicly disclose information identifying each TALF Borrower and each Material Investor of a TALF Borrower.
Moreover, if an investment fund or any of its affiliates originates loans, such fund may not securitize such loans, acquire the triple-A-rate tranche of the securitization and finance it using the TALF 2.0.
Representations and Certifications
While the New York Fed will be providing further detailed instructions regarding borrower certifications at a later date, a TALF Borrower will be required to certify that it (a) complies with the conflicts of interest requirements of section 4019 of the Coronavirus Aid, Relief, and Economic Security Act; (b) is not insolvent; and (c) is unable to secure adequate credit accommodations from other banking institutions. With regard to (c), an inability to secure adequate credit may be based on unusual economic conditions in the market or markets intended to be addressed by the TALF 2.0. For example, while lending may be available from other banking institutions, the conditions or prices are inconsistent with a well-functioning market. Lack of adequate credit does not mean that no credit is available.
Under the MLSA, each TALF Borrower will make a continuous representation that it is an eligible borrower, continuously meeting the eligibility requirements set forth in the New York Fed’s FAQs: Term Asset-Backed Securities Loan Facility. It will also be required to disclose all Material Investors and, for as long as the TALF 2.0 loan is outstanding, disclose any new Material Investor.
Additional information regarding the TALF 2.0 and other borrower types can be found in the New York Fed’s FAQs: Term Asset-Backed Securities Loan Facility.[3]
Schulte Roth & Zabel is working with several clients to participate in the TALF 2.0 and will continue to provide updates as further developments become known. In the meantime, please contact your SRZ attorney or one of the authors if you have any questions.
Authored by Craig Stein, Joseph P. Vitale and David Rosenberg.
[1] See SRZ Alert, “New Term Asset-Backed Securities Loan Facility Established by Federal Reserve in Wake of COVID-19,” April 2, 2020, available here.
[2] For this purpose, an investment fund includes (1) any type of pooled investment vehicle that is organized as a business entity or institution, including without limitation, a hedge fund, a private equity fund, and a mutual fund; and (2) any type of single-investor vehicle that is organized as a business entity or institution. Eligible investment funds may be newly-formed and may include those that only borrow from the TALF 2.0 and only invest in the TALF 2.0 eligible asset-backed securities (“ABS”), as well as investment funds that invest in a variety of assets and the TALF 2.0 eligible ABS.
This is a fast-moving topic and the information contained in this Alert is current as of the date it was published.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

TALF 2.0: CLOs as Eligible Collateral
ARTICLE / CLIENT ALERT
TALF 2.0: CLOs as Eligible Collateral
May 13, 2020
Read time: 8 min
On March 23, 2020, the Board of Governors of the Federal Reserve System (“Federal Reserve”) authorized the Federal Reserve Bank of New York (“New York Fed”) to establish the Term Asset-Backed Securities Loan Facility (“TALF 2.0”).[1] TALF 2.0 is intended to facilitate the issuance of eligible asset-backed securities (“ABS”) to stabilize ABS markets to counter disruptions associated with COVID-19. Under TALF 2.0, the New York Fed will commit to lend funds to a special purpose vehicle (“TALF SPV”) which will make loans (“TALF Loans”) available to eligible borrowers on a non-recourse basis, to be fully secured by eligible ABS collateral. The TALF SPV will initially make up to $100 billion of loans available. Each TALF Loan will have a maturity of three years, will be pre-payable in whole or in part at the option of the borrower and will be issued pursuant to a master loan and security agreement. TALF 2.0 will be available until Sept. 30, 2020, unless the program is extended.
The New York Fed issued FAQs and updated terms and conditions for TALF 2.0 on May 12, 2020, with guidance on what types of CLOs would be deemed eligible collateral for a TALF Loan.
Eligibility Criteria for All ABS under TALF 2.0
In order to qualify as eligible collateral under TALF 2.0, ABS must have the following characteristics:
- S. dollar denominated cash ABS (not synthetic);
- A credit rating in the highest long-term, or, if no long-term rating is available, the highest short-term investment-grade rating category from at least two eligible, nationally recognized statistical rating organizations (“NRSROs”);
- No credit rating below the highest investment-grade rating category from an eligible NRSRO;
- Issued after March 23, 2020 (other than CMBS, which must be issued before March 23, 2020, and SBA Pool Certificates and Development Company Participation Certificates, which must be issued after Jan. 1, 2019);
- All or substantially all of the underlying credit exposures:
- Must be newly issued (except for CMBS);
- For new issue ABS, except CLOs, must be originated by U.S.-organized entities (including U.S. branches or agencies of foreign banks);
- Must be to U.S.-domiciled obligors or with respect to real property located in the United States or one of its territories[2];
- No exposures that are cash ABS or synthetic ABS; and
- Does not have interest payments that step up or step down to predetermined levels on specific dates.
Eligibility Criteria for CLOs under TALF 2.0
In order to qualify as eligible collateral under TALF 2.0, CLOs must have the characteristics required for all ABS (unless CLOs are expressly excluded from such criteria) and also have the following characteristics:
- The CLO is a static CLO[3] collateralized by leveraged loans;
- Not backed by commercial real estate;
- An average life equal to or less than 10 years;
- Have a manager that has its principal place of business in the United States;
- All, or substantially all, of the underlying exposures have a lead or co-lead arranger that is a U.S.-organized entity (which includes a U.S. branch or agency of a foreign bank)[4];
- All, or substantially all, of the underlying leveraged loans are:
- Broadly syndicated loans to large corporate borrowers and/or middle-market loans;
- Senior secured loans;
- Originated no later than Jan. 1, 2019 (newly originated leveraged loans may include loans that have been refinanced on or after Jan. 1, 2019);
- Current on principal and interest;
- Subject to the following portfolio limitations and terms as of the date of the TALF Loan subscription:
- Maximum second lien loan concentration of 10%;
- Maximum debtor in possession (DIP) loan concentration of 7.5%;
- Maximum covenant lite loan concentration of 65% for broadly syndicated CLOs[5] and 10% for middle-market CLOs[6];
- Maximum single underlying obligor concentration of 4%; and
- The CLO includes at least one overcollateralization test redirecting cash flow from the equity and subordinated tranches to the TALF-eligible senior tranche in the event of deterioration in the underlying loan portfolio.
Additionally, leveraged loans with interest rates tied to LIBOR are generally expected to have adequate fallback language and the CLOs themselves will be expected to have acceptable LIBOR fallback language.[7]
Collateral Valuation for CLOs
Pledged eligible collateral will be valued and assigned a “haircut” according to a schedule based on its sector, the weighted average life and historical volatility of the ABS. If an eligible CLO has an average life from zero to five years, it will be subject to a 20% haircut, and if an eligible CLO has an average life from five to 10 years, it will have a haircut percentage that will increase by one percentage point for each additional year (or portion thereof) of average life beyond five years.
Pricing and Fees for CLOs
Under TALF 2.0, TALF Loans financing CLOs will be subject to an interest rate of 150 basis points over the 30-day average Secured Overnight Financing rate (“SOFR”), to be paid quarterly. Additionally, CLO borrowers will be subject to a 10 basis points administrative fee assessed against the loan amount on the settlement date for collateral.
Schulte Roth & Zabel will continue to provide updates as further developments become known. In the meantime, please contact your SRZ attorney or one of the authors if you have any questions.
Authored by Craig Stein, Phillip J. Azzollini, Daniel V. Oshinsky, James V. Williams, III and Sanjana V. Nafday.
[1] See https://www.federalreserve.gov/newsevents/pressreleases/files/monetary20200323b3.pdf.
[2] “For newly issued CLOs, 95% or more of the dollar amount of the underlying loans in the CLOs must be exposures that are (1) arranged by a lead or a co-lead arranger that is a U.S.-organized entity (including a U.S. branch or agency of a foreign bank) and (2) made to U.S.-domiciled obligors.”
[3] A static CLO is “a CLO that does not include a period of reinvestment of collateral proceeds, including principal or interest proceeds and proceeds on the sale of defaulted underlying leveraged loans, unless such period of reinvestment begins at least three years after the disbursement date of any TALF loan secured by the pledge of such CLO. Additionally, a static CLO shall not permit reinvestment of proceeds at any time when the senior-most tranche in priority of payment (or, if the CLO structure includes multiple senior tranches that are pari passu in priority of payment, one or more of such senior tranches) is owned by the New York Fed or by the TALF SPV.” Eligible CLOs may permit loans to be sold for cash at their par amount, plus accrued interest, to a sponsor where the cash proceeds are applied to amortize the CLO. CLO managers may sell underlying loans that have defaulted in payment of principal and interest; however the sale proceeds may not be reinvested and must be used to amortize the CLO.
[4] See footnote 2.
[5] A broadly syndicated CLO is a CLO that does not include leveraged loans of obligors with potential indebtedness of less than $150 million and permits no more than 10% of the portfolio to be comprised of leveraged loans to obligors with total potential indebtedness of $150 million to $250 million. See “FAQs: Term Asset-Backed Securities Loan Facility,” May 12, 2020, “What is the definition of a broadly syndicated CLO and a middle market CLO?”
[6] A middle-market CLO is a CLO that is composed of leveraged loans of obligors, all or substantially all of which have potential indebtedness of less than $250 million but does not permit the portfolio to include leveraged loans of obligors with EBITDA of less than $10 million. Id.
[7] Note, further that a CLO will not be eligible collateral for a borrower if such borrower or its affiliate is a borrower under a leveraged loan backing such CLO, unless that loan, and each other leveraged loan in the CLO loan portfolio made to an affiliate of the TALF Loan borrower, together constitute no more than 4% of the aggregate principal balance of the leveraged loans in the loan portfolio as of the subscription date.
This is a fast-moving topic and the information contained in this Alert is current as of the date it was published.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

Hospital at Home – CMS Expands Payments to Hospitals for Care Provided in Patient Homes
ARTICLE / CLIENT ALERT
Hospital at Home – CMS Expands Payments to Hospitals for Care Provided in Patient Homes
May 12, 2020
Read time: 8 min
On April 30, 2020, the Centers for Medicare and Medicaid Services (CMS) published an interim final rule (IFR) that made regulatory changes and clarified certain policies in response to the Coronavirus (COVID-19) public health emergency (PHE). The IFR’s changes include increased flexibilities for hospitals to provide and receive Medicare payment for hospital outpatient services to patients in their homes.
Throughout the COVID-19 PHE, CMS has made an unprecedented effort to respond quickly and comprehensively to the needs of hospitals tasked with providing critical patient care services in a safe and secure environment. In light of hospital infection control concerns and space use challenges during the COVID-19 PHE, CMS will permit hospitals to treat temporary expansion locations as provider-based departments of the hospital, so long as such treatment is not inconsistent with the state’s emergency preparedness or pandemic plan. When a hospital relocates services from within a hospital location to temporary expansion locations, such temporary expansion locations could include a patient’s home. Under this flexibility, CMS will permit Medicare payment for services furnished to a patient in her home when the hospital considers the home to be a relocated outpatient location of the hospital. For outpatient services furnished in these “hospital-at-home” locations, Medicare coverage includes services furnished in-person, remotely or by telehealth.
Hospital Services in a Temporary Expansion Location
Enrollment
CMS will not require that hospitals enroll hospital-at-home locations as locations of the hospital. No updates are required to a hospital’s CMS 855A/PECOS enrollment record. However, if the “original” location of the service that was relocated to the patient’s home was treated as an “excepted” location for purposes of the Medicare Outpatient Prospective Payment System (OPPS) site-neutral payment rules, the hospital can continue to receive the full OPPS rate for the relocated services if additional materials are submitted to CMS.
Services Provided in Hospital-at-Home Locations
Under the hospital-at-home model, hospitals can receive payment for hospital facility fees associated with certain “hospital therapeutic services” covered under 42 CR 410.27 when furnished by hospital clinical staff, including outpatient therapy, counseling and educational services. These services do not include a separate professional services fee, so the only payment received by the hospital when the services are furnished in the hospital is the facility fee. Therefore, the hospital can continue to bill the facility fee for services furnished in the patient’s home because the patient’s home is treated as a location of the hospital. Such services are subject to general supervision, unless CMS has explicitly required a higher level of supervision.
Further, for those services that CMS has determined do not require in-person performance and would otherwise cover when furnished in the hospital if the patient and hospital staff were not in the same location, CMS will continue to permit the hospital to bill for a facility fee when those services are furnished remotely to a patient in his home by hospital staff. CMS makes clear in the IFR that this payment is not being made under the telehealth benefit or expanded telehealth flexibilities under the PHE. As a result, the hospital payment is not for an “originating site facility fee,” but rather the full hospital facility fee applicable to the service provided (e.g., G0463). The coverage is provided by virtue of the treatment of the patient’s home as a location of the hospital. Hospitals should evaluate each service being provided under the hospital-at-home model to determine whether it can be provided remotely or must be provided in-person. Examples of services that could be provided remotely are behavioral health counseling, certain rehabilitation therapy services and genetic counseling. Examples of services that must be provided in-person are infusion, wound care and drug administration.
Because the payment is being made based on treatment of the patient’s home as a location of the hospital, the OPPS site-neutral rules apply to the location. If the “original” location of the service that was relocated to the patient’s home was subject to the site-neutral payment rules (i.e., payment reduced from the full OPPS rate to the “applicable fee schedule amount”), payment for the service in the patient’s home will continue at the reduced site-neutral rate and should be billed with the “PN” modifier. If, however, the “original” location of the service was an “excepted” location under the site-neutral payment rules (including on-campus locations), the hospital must either accept the lower site-neutral payment rate for services furnished in the patient’s home or submit additional documentation to CMS to preserve the higher OPPS rate.
CMS will continue payment at the higher OPPS rate, which include the COVID-19 PHE. CMS also modified the application process and extended the reporting timeframe for “extraordinary circumstances” relocation requests. Excepted locations that relocate services to a patient’s home (or any other temporary location) on or after March 1, 2020, for the purposes of addressing the COVID-19 PHE must submit documentation to the applicable CMS Regional Office providing notice and supporting details of the relocation within 120 days of beginning to provide services at the relocated site. The submission to the Regional Office must include:
- The hospital’s CCN
- The address of the current outpatient department
- The address of the relocated outpatient department
- The date the hospital began providing services at the relocated outpatient department
- A justification for the relocation and the role of the relocation in the hospital’s response to the COVID-19
- An attestation that the relocation is not inconsistent with the state’s emergency preparedness or pandemic plan.
CMS will not require separate justification for each patient home address, but will require a submission generally related to services provided in patient homes. All other relocations require separate identification of the specific location to which services are relocated, but CMS indicated that these addresses can be combined into a single submission. Services that are relocated under the “extraordinary circumstances” exception can continue billing as “excepted” services with the “PO” modifier without a gap, and do not have to wait for CMS approval of the “extraordinary circumstances” submission.
CMS further clarified that the extraordinary circumstances exception is available only for “relocated” locations, not for “new” locations. All new locations are subject to payment under the reduced site-neutral rates, although CMS also stated that a hospital can partially relocate services, such that the services may continue at the original location, despite some portion of the service being relocated.
Hospital Services Accompanying a Professional Service Furnished via Telehealth
The IFR generally speaks to the hospital-at-home model in the context of hospital services provided remotely. In this regard, the hospital services provided under this model are not “telehealth services.” Because CMS treats the patient’s home as a location of the hospital, the hospital bills for the services of hospital clinical staff using a hospital facility fee, as if the services were furnished in the hospital. However, under the IFR, CMS also clarified that because the hospital-at-home model treats the patient’s home as a location of the hospital, the hospital is eligible for a telehealth “originating site fee” when a hospital-based practitioner who can separately bill for professional services furnishes services via telehealth to a patient receiving hospital services at home under the hospital-at-home model. Previously, only the professional claim could be submitted for telehealth services provided to a patient located at home. This change, which applies to services performed on or after March 1, 2020, puts hospitals on more equal footing with clinics and physician practices with respect to reimbursement for telehealth services.
Additional Considerations
The hospital-at-home model provides significant flexibilities to hospitals responding to COVID-19 concerns related to infection control and hospital space use, and provides opportunities to recoup some lost revenue that might occur if a patient cannot receive services in the hospital. Although the IFR introduces significant opportunities, hospitals also must maintain awareness of the limitations surrounding the hospital-at-home model. For instance, CMS still requires that the hospital’s relocation be consistent with its state’s emergency preparedness or pandemic plan. Hospitals should maintain communication with their state departments of health to ensure that any action taken aligns with the state response to the COVID-19 PHE and any other applicable state laws or regulations.
The model proposed by CMS in the IFR only applies to Medicare beneficiaries. Other payors may not, and are under no federal obligation to, follow Medicare’s lead.
Finally, hospitals using the hospital-at-home model should ensure that the model is appropriate for each individual patient given the service provided and the specific home environment, and should consider the potential additional liability and insurance risks posed by furnishing services as hospital services to the patient in her home.

The IRS Cares: FAQs on Retirement Plan Distributions, Loans Under the CARES Act
ARTICLE / CLIENT ALERT
The IRS Cares: FAQs on Retirement Plan Distributions, Loans Under the CARES Act
May 12, 2020
Read time: 4 min
The Internal Revenue Service recently issued questions and answers regarding the special distribution, rollover and loan provisions for tax-qualified retirement plans under the Coronavirus Aid, Relief and Economic Security Act.
The Internal Revenue Service (IRS) issued a first round of answers to frequently asked questions (FAQs) regarding the special coronavirus-related distribution, rollover and loan provisions for tax-qualified retirement plans under the Coronavirus Aid, Relief and Economic Security (CARES) Act.
Background
The CARES Act provides that an eligible retirement plan (such as a 401(k) plan, a 403(b) plan or an IRA) may allow a qualified individual to take a coronavirus-related distribution of up to $100,000, taxable ratably over three years unless repaid within three years after the distribution was received. The CARES Act also allows an eligible retirement plan to increase the loan limit for a qualified individual, up to the lesser of $100,000 (minus outstanding plan loans of the individual), or 100% of the individual’s vested benefit under the plan. The CARES Act permits a plan to provide qualified individuals with up to an additional year to repay plan loans.
A retirement plan participant is a “qualified individual” if:
The participant, or his or her spouse or dependent, is diagnosed with the virus SARS CoV‑2 or with COVID-19 (diagnosed by a test approved by the Centers for Disease Control and Prevention), or
The participant experiences “adverse financial consequences” due to (1) being quarantined, laid off or furloughed, or having work hours reduced due to SARS CoV‑2 or COVID-19; (2) being unable to work because of lack of child care due to SARS CoV‑2 or COVID-19; (3) the closing or reduced hours of a business that the participant owns or operates due to SARS CoV‑2 or COVID-19; or (4) other factors identified by the US Department of the Treasury and the IRS.
IRS FAQs
The FAQs confirm that the Treasury Department and the IRS are working on additional guidance to address the CARES Act provisions for retirement plans and IRAs. The Treasury Department and the IRS anticipate that the guidance will apply the principles of IRS Notice 2005-92 related to the Katrina Emergency Tax Relief Act of 2005 (KETRA) where applicable. For now, the KETRA guidance provides a roadmap for plan sponsors as they begin to address the tax and reporting issues related to the CARES Act provisions.
The FAQs include the following information:
- The CARES Act provisions for coronavirus-related distributions and loans are optional for plan sponsors to adopt.
- An eligible distribution made to a qualified individual on or before December 30, 2020, can be treated as a coronavirus-related distribution for tax purposes, regardless of whether the plan offers such distributions. For example, if a qualified individual takes an in-service withdrawal between January 1, 2020, and December 30, 2020, from a 401(k) plan that does not offer coronavirus-related distributions, the participant may report the withdrawal as a coronavirus-related distribution on his or her tax return, subject to the limits on such distributions.
- The Treasury Department and the IRS are reviewing public comments and considering whether to expand the list of factors to determine whether a person is a “qualified individual.”
- For loans to qualified individuals that are outstanding between March 27, 2020, and December 31, 2020, any repayment may be delayed by up to one year. Repayments must be amortized to reflect the delay and accrued interest during the delay.
- The CARES Act does not change the rules for permitted distributions under pension plans, including the qualified joint and survivor annuity requirements.
- A plan that does not otherwise accept rollover contributions is not required to accept repayments of coronavirus-related distributions.
- Plan administrators must report a participant’s coronavirus-related distribution on Form 1099-R even if the participant repays the distribution in the same year.
For retirement plans that offer coronavirus-related relief under the CARES Act, plan sponsors and administrators should consider the FAQs in administering the CARES Act provisions, and can obtain more information on the FAQs from their McDermott employee benefits lawyer or one of the listed authors.

Time Limitations Are the Achilles Heel of Cryptocurrency Securities Class Actions
ARTICLE
Time Limitations Are the Achilles Heel of Cryptocurrency Securities Class Actions
May 12, 2020
Read time: 2 min
Reprinted with permission from the 12th May issue of New York Law Journal (c) 2020 ALM Media Properties, LLC. All rights reserved. Further duplication without permission is prohibited, contact 877-257-3382 or reprints@alm.com.